On October 20, 2026 IDP Pharma reported that the first patient has been dosed in MYCROCYTIC, a multicentre Phase Ib/II study evaluating IDP-121 in combination with standard-of-care chemotherapy in patients with relapsed small cell lung cancer (SCLC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IDP-121 is an investigational peptide therapeutic designed to directly inhibit MYC and promote its degradation. Discovered using the company’s proprietary Intrametrics platform, it targets a protein implicated in tumour proliferation, cellular plasticity and treatment resistance.

The study is expected to enrol approximately 60 patients across nine centres in Spain. It will evaluate IDP-121 in combination with topotecan in patients with platinum-refractory or resistant disease, and with platinum rechallenge in patients with platinum-sensitive disease. The primary objectives are to assess safety and tolerability and establish preliminary clinical proof-of-concept.

MYCROCYTIC expands the clinical development of IDP-121 into solid tumours following completion of CASSANDRA, its first-in-human Phase I programme in relapsed or refractory haematological malignancies.

"This study represents an important milestone in the evolution of our clinical pipeline and reflects our strategy of translating breakthrough science into medicines for patients with high unmet medical need," said Dr. Santiago Esteban, Chief Executive Officer of IDP Pharma.

IDP Pharma thanks the patients, their families and the participating clinical teams for their contribution to this research.

(Press release, IDP Pharma, OCT 20, 2026, View Source [SID1234673604])

On October 20, 2026 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, reported new data at an investor event in New York City from the ARC-20 platform study, which is evaluating casdatifan, an investigational next-generation HIF-2α inhibitor, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma (ccRCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Across the RCC treatment continuum, and in every setting in which it has been studied, casdatifan has shown rapid disease control, a meaningful impact on survival, and was tolerable, both alone and in combination with standard-of-care therapies," said Dr. Rana McKay, professor of medicine, urology, and radiation medicine, associate director of clinical sciences, at the UC San Diego Moores Cancer Center. "These are the attributes that matter most to physicians and patients."

"We are executing on a plan to develop casdatifan as a backbone therapy for all ccRCC patients," said Richard Markus, M.D., Ph.D., chief medical officer at Arcus Biosciences. "The disease control that has been observed for casdatifan plus anti-PD-1 in the first line, the remarkable benefit that has been observed for patients in the second line, even after progressing on prior TKI treatment, and unprecedented three-year median overall survival from casdatifan monotherapy in patients who had progressed on multiple prior therapies reveal for the first time the potential associated with deep and durable HIF-2α inhibition. We are on track to initiate our second registrational trial in ccRCC, the first-line PEAK-20 study, by the end of this year. This study is enabled by the strong dataset we have generated in the first-line setting."

New data were presented from several cohorts of the ARC-20 study, which showed that every patient has the opportunity to benefit from casdatifan across each line of therapy over the course of their care. All cohorts had a data cut-off (DCO) of Sept. 4, 2026, and the data are summarized below. A detailed analysis can be accessed in a corporate deck published on the company’s website.

First-line TKI-free combinations:

Casdatifan plus anti-PD-1 zimberelimab (11.5 months of median follow-up)
Landmark PFS values of 86% and 69% were observed at 6 and 12 months, respectively in this cohort (n=30), which far exceeded benchmarks for anti-PD-1 (pembrolizumab) monotherapy (61% and 38%) and the standard-of-care anti-PD-1 plus anti-CTLA-4 (ipilimumab and nivolumab) combination (65% and 50%) in this setting (Figure 1). These landmark values also compare favorably with benchmarks for approved anti-PD-1 plus TKI regimens.
A 50% confirmed objective response rate (cORR) and 6.7% (n=2) rate of primary progression(progression at or before first scan) were observed, indicating early tumor control. These data compare favorably with benchmarks for pembrolizumab (36% cORR and 30% primary progression) and the ipilimumab and nivolumab combination (39% cORR and 20% primary progression) in this setting.
No unexpected safety signals were observed at the time of DCO (n=30). The regimen has shown safety data that are consistent with those observed in other cohorts or prior studies of each molecule.
Figure 1: 1L casdatifan (cas) + zimberelimab (zim) vs. immunotherapy benchmarks (KEYNOTE-427, CheckMate-214)
Figure 1: 1L casdatifan (cas) + zimberelimab (zim) vs. immunotherapy benchmarks (KEYNOTE-427, CheckMate-214)
Casdatifan plus ipilimumab plus zimberelimab (3 months of median follow-up)
Only one patient experienced primary progression (4%, n=24 with at least one scan).
No unexpected safety signals were observed at the time of DCO (n=31).
Safety data from this cohort are expected to support initiation of PEAK-20, the planned 1L registrational trial evaluating casdatifan plus ipilimumab plus nivolumab, expected to start in the fourth quarter of 2026.
Second-line casdatifan plus cabozantinib combination (21.3 months of median follow-up):

A 14.5-month median PFS (mPFS) was reached in patients (n=43) treated with casdatifan plus cabozantinib, far exceeding benchmarks for cabozantinib in this setting (~10 months mPFS). The 18-month landmark OS was 77% for the combination (compared to ~60% for cabozantinib benchmarks in this setting [Figure 2]), cORR was 44% and primary progression was 5%.
Casdatifan plus cabozantinib demonstrated impressive efficacy, including in patients who had progressed on a prior TKI therapy. TKI-pretreated patients represent approximately 60% of 2L patients in current practice and derive diminished benefit from subsequent TKI therapies. The efficacy of casdatifan plus cabozantinib was similar to that of patients who had not received a TKI in their prior treatment.
No unexpected safety signals were observed at the time of DCO (n=44). The regimen has shown safety data that are consistent with those observed in other cohorts or prior studies of each molecule.
Arcus is evaluating casdatifan plus cabozantinib, the most prescribed TKI, for the 2L treatment of ccRCC in the ongoing registrational Phase 3 PEAK-1 study.
Figure 2: 2L casdatifan (cas) + cabozantinib (cabo) OS vs. cabozantinib benchmarks
Figure 2: 2L casdatifan (cas) + cabozantinib (cabo) OS vs. cabozantinib benchmarks
Late-line casdatifan monotherapy (28 months of median follow-up):

A 35-month median OS (mOS), 13-month mPFS and 36% cORR were observed in the four pooled monotherapy cohorts (n=121), which evaluated casdatifan in heavily pre-treated patients with metastatic ccRCC (52% had received at least three prior lines of therapy), including both an anti-PD-1 and a VEGFR TKI. The four pooled monotherapy cohorts included: 50mg once daily (QD), 50mg twice daily (BID), 100mg QD (tablet) and 150mg QD. Casdatifan demonstrated improvements across each of the key efficacy measures relative to data from benchmark studies with a first-generation HIF-2α inhibitor (Figure 3).
PFS data were similar whether patients had received one, two or three prior TKI-inclusive treatments, in contrast to what has been reported for the only approved HIF-2α inhibitor, which showed an inverse correlation between efficacy and more prior TKI-inclusive therapies in a similar patient population (LITESPARK-013).
No unexpected safety signals were observed, and casdatifan showed acceptable and manageable adverse events across all doses.
Arcus plans to initiate a registrational trial evaluating casdatifan plus tivozanib compared to tivozanib.

Arcus is hosting an in-person and virtual investor event in New York today, beginning at 5:30 AM PT / 8:30 AM ET, to review the new casdatifan data. Investors may register and log in to the live webcast using the following link: https://event.summitcast.com/view/oP6P82VnbjK87kUbV5QALF/guest_book?session_id=WJm4z43QhGbWA8FEbbv5AM. To access a replay of the event and accompanying slide presentation, please visit the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com.

About Casdatifan (AB521)

Casdatifan is a small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α), a master switch that turns on hundreds of genes in response to low oxygen levels. In a majority of people with the most common form of kidney cancer (clear cell renal cell carcinoma), genetic anomalies result in the dysregulation of this master switch and transformation of normal kidney cells into cancerous ones.

Casdatifan was designed to provide deep and durable inhibition of the HIF-2α pathway. Early clinical studies have shown high response rates and a low primary progression rate relative to clinical benchmarks, warranting further investigation in late-stage studies. Casdatifan, which is administered in pill form once daily, has shown safety data that allow it to be investigated in combination with other treatments.

The casdatifan development strategy is designed to generate evidence needed to establish casdatifan as a backbone therapy so that every ccRCC patient has the opportunity to benefit from casdatifan across each line of therapy. In addition to partner-operationalized studies, including combinations with casdatifan and anti-PD-X/VEGF bispecifics, Arcus is investigating casdatifan across multiple cohorts in the ARC-20 platform study, alone and in combination with other potential new treatment options, including in:

The first-line setting with cohorts evaluating casdatifan plus zimberelimab, an anti-PD-1 (ongoing); casdatifan plus zimberelimab and ipilimumab, an anti-CTLA-4 (ongoing); and casdatifan plus ivonescimab, an anti-PD-1/VEGF bispecific (ongoing)
The second-line setting with a cohort evaluating casdatifan plus cabozantinib, a TKI, in immunotherapy-experienced patients (ongoing)
The late-line setting with a cohort evaluating casdatifan plus tivozanib, a TKI, in HIF-2α inhibitor-experienced patients (planned)
Arcus is also enrolling PEAK-1, the global Phase 3 study evaluating casdatifan plus cabozantinib versus cabozantinib in immunotherapy-experienced patients with metastatic ccRCC.

Casdatifan is an investigational molecule. Approval from any regulatory authority for its use has not been received, and its safety and efficacy have not been established. Taiho has development and commercial rights in Japan and other countries in Asia, excluding China. Arcus Biosciences holds full rights to casdatifan everywhere else globally.

About RCC

According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,450 Americans will be diagnosed with kidney cancer in 2026. Clear cell RCC is the most common type of kidney cancer in adults. If detected in its early stages, the five-year survival rate for kidney cancer is high; for patients with advanced or late-stage metastatic kidney cancer, however, the five-year survival rate is only 19%. For metastatic kidney cancer, targeted drug therapies are one of the main treatment options.

(Press release, Arcus Biosciences, OCT 20, 2026, View Source [SID1234673603])

On October 20, 2026 AstraZeneca and Oracle Health and Life Sciences reported a unique collaboration to leverage AstraZeneca’s scientific, clinical development and regulatory expertise with Oracle’s real-world data, cloud infrastructure, and AI-enabled clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to accelerate clinical trial optimisation and help more patients receive the right care sooner.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Many serious conditions are diagnosed late; patients can wait a long time before they are referred and there are gaps in how we translate scientific advancements into clinical practice. This collaboration is designed to test practical ways to connect scientific research directly to clinical workflows and transform care. Initial areas of exploration include clinical trial recruitment, earlier diagnosis, drug-safety monitoring and leveraging real-world evidence across the lifecycle of a medicine. Programmes will span AstraZeneca’s core disease areas including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare disease.

The collaboration will span multiple international projects with key regions including the US, Middle East, and Europe working with local governments and within applicable regulations to ensure these could be scaled in the future. The first programme will focus on supporting hypertension care and clinical research in Abu Dhabi, in partnership with healthcare company, M42. This will help clinical teams identify patients with uncontrolled hypertension; implementing guideline-directed care; and improving the recruitment for clinical trials.

Pascal Soriot, Chief Executive Officer, AstraZeneca said: "This unique collaboration brings leaders in healthcare and AI together at a global scale to accelerate the journey from the discovery of medicine to patient care. Combining AstraZeneca’s world class science with Oracle’s deep data and technology expertise, we can help clinicians identify patients sooner, optimise clinical trials, and generate evidence continuously across the lifecycle of a medicine."

Mike Sicilia, chief executive officer, Oracle said: "Some of the most important opportunities for AI are in healthcare, where better use of data can help turn scientific innovation into better outcomes for patients. By bringing AstraZeneca’s scientific expertise together with Oracle’s data, cloud, AI, and healthcare capabilities, we have an opportunity to help accelerate research, connect more patients to clinical trials, and ultimately bring relevant insights into care faster."

Anne-Claire Gerbaldi, Chief Digital, Data and AI Officer, AstraZeneca, said: "Too many patients are diagnosed late or face a long journey to get the care they need. To build the next decade of medicine, we aim to harness AI to connect learnings across science, clinical trials and everyday care, generating insights that continuously strengthen research, accelerate innovation, and enhance patient outcomes. Bringing together the unique capabilities of Oracle and AstraZeneca, we believe we can support smarter clinical trials, strengthen safety monitoring and help ensure patients are diagnosed sooner and receive the right care."

Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, said: "Healthcare progress depends on shortening the distance between scientific insight and the decisions clinicians make every day. AstraZeneca brings deep scientific and therapeutic expertise, and Oracle will deliver the secure data, cloud, AI, and clinical workflow capabilities. This collaboration has the potential to help health systems identify eligible patients sooner, broaden access to clinical trials, and generate evidence that supports the next decision, all under the governance of the health systems delivering care."

The collaboration will use deidentified real-world data within robust governance, privacy and security arrangements. AstraZeneca will not receive patient-identifiable information. Each proposed project will be reviewed separately and will only proceed once appropriate legal, privacy, regulatory, ethical and institutional safeguards are in place. The companies have signed a non-binding term-sheet agreement. No financials are being disclosed as part of this agreement.

(Press release, AstraZeneca, OCT 20, 2026, View Source [SID1234673567])

On October 19, 2026 Quanta Therapeutics, a privately held, clinical-stage biopharmaceutical company leading the development of innovative therapeutics for RAS-driven cancers, reported that it will present clinical data for its oral, G12D-preferring multi-KRAS inhibitor QTX3034 in combination with cetuximab with or without FOLFOX chemotherapy in patients with CRC at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress taking place October 23-27 in Madrid, Spain. Quanta also announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to QTX3034 for the treatment of KRASG12D-mutant CRC in combination with cetuximab, with or without FOLFOX chemotherapy, the same treatment regimens for which clinical data will be presented at ESMO (Free ESMO Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting new clinical data at ESMO (Free ESMO Whitepaper) highlighting the potential of QTX3034-based combinations to improve outcomes for patients with KRASG12D-mutant CRC," said Perry Nisen, M.D., Ph.D., Chief Executive Officer of Quanta. "We are particularly pleased that these data supported the FDA’s decision to grant Fast Track designation for QTX3034 in this patient population. We believe this represents the first Fast Track designation based on clinical data for a KRAS G12D-targeted therapy in CRC, underscoring the significant unmet need in this population and the importance of advancing innovative treatment options for these patients."

ESMO presentation information:
Title: Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor, in combination with cetuximab ± mFOLFOX6 in patients with KRASG12D-mutated colorectal cancer (CRC)
Session Date and Time: Saturday, October 24, 2026; 2:45-4:15 pm CEST
Session Name: Rapid oral: Gastrointestinal tumours, lower digestive
Abstract Number: 790RO

About FDA Fast Track Designation
FDA’s Fast Track designation is intended to facilitate and expedite the development and review of new drugs to treat serious or life-threatening conditions. To qualify, available clinical and non-clinical data need to demonstrate the potential to address unmet medical need. The benefits of Fast Track designation include opportunities for frequent meetings with the FDA to discuss trial design, development plans and data needed to support drug approval, as well as the ability to submit a New Drug Application (NDA) on a rolling basis, and eligibility for priority review, if relevant criteria are met. For more information on the Fast Track process, please visit the FDA’s official website.

(Press release, Quanta Therapeutics, OCT 19, 2026, View Source [SID1234673602])

On October 19, 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) reported it will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting, held from 23 to 27 October in Madrid.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our presentations at ESMO (Free ESMO Whitepaper) 2026 highlight the depth and impact of Roche’s oncology pipeline, driven by emerging science capable of bringing new treatment benefits across diverse and high-unmet-need cancers," said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. "From establishing head-to-head superiority with divarasib in KRAS G12C-mutated lung cancer to advancing patient-centered oral SERD therapies like giredestrant and next-generation ADCs such as Tam-Peli, we are committed to delivering medicines that not only extend life, but also seek to improve treatment experience, tolerability and quality of life for people living with cancer.

Divarasib demonstrated superior efficacy and best-in-class potential in KRAS G12C NSCLC
Roche will share phase III Krascendo 1 results, which demonstrated divarasib’s best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer.

Krascendo 1 is the only global head-to-head trial to evaluate a next-generation KRAS G12C inhibitor versus approved first-generation inhibitors.1
Results for this potential best-in-class, next-generation KRAS G12C-targeted therapy will be presented as a late-breaking abstract during a Presidential Symposium.
Giredestrant data support its potential to become the new standard of care in early-stage and advanced breast cancer
Roche will present new data highlighting the potential role of giredestrant, an investigational, oral, potent next-generation selective oestrogen receptor degrader (SERD) and full antagonist,2 in oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, a subtype in which more than 90% of cases are diagnosed at an early-stage (I-III).3-6 Key presentations from early-stage to advanced disease include:

Patient-reported outcomes from the phase III lidERA Breast Cancer trial suggesting that the improved efficacy of giredestrant compared to endocrine therapy is achieved without compromising tolerability or Health-Related Quality of Life.
Exploratory biomarker findings from the evERA Breast Cancer trial of giredestrant in combination with everolimus in ER-positive, HER2-negative advanced breast cancer in the post-cyclin-dependent kinase 4/6 inhibitor setting.
Updated interim results for giredestrant plus inavolisib from the MORPHEUS Breast Cancer trial evaluating giredestrant treatment combinations in ER-positive, HER2-negative locally advanced or metastatic breast cancer.
Data demonstrate the potential of a next generation B7-H3 targeted antibody-drug conjugate (ADC) Tam-Peli (tambotatug pelitecan)
New data will also be presented for Tam-Peli, an investigational next generation B7-H3-targeted ADC designed to deliver high-potency anti-tumour activity while limiting off-target toxicity.7 Tam-Peli is currently being investigated across multiple solid tumour indications:

ESMO data include late-breaking interim phase III results in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma, analyses of interstitial lung disease in patients with advanced solid tumours from phase I/II studies, and phase I efficacy and safety data for Tam-Peli in patients with locally advanced or metastatic NSCLC.
These findings build on the TAISHAN-302 phase III data in second-line small cell lung cancer presented at the World Conference on Lung Cancer in September, where the study met all three specified endpoints of overall survival, progression free survival and objective response rate at its first interim analysis.
Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, and Macau, and plans to rapidly initiate global trials across multiple tumour types.
Overview of key presentations featuring Roche medicines and molecules:

Medicine or molecule Abstract title Abstract number/ presentation details
Lung cancer
Divarasib Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC. #LBA5 Proffered Paper Session

Presidential Symposium II

Sunday 25.10.2026
16:30 – 16:42 CET
Divarasib Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer. #2551 TiP Poster

NSCLC, Early-Stage

Monday 26.10.2026
12:00 – 12:45 CET
Tam-Peli Tambotatug pelitecan (YL201): Efficacy and safety in locally advanced/ metastatic NSCLC from a phase I study. #2577 Poster

NSCLC, Locally Advanced

Monday 26.10.2026
12:00 – 12:45 CET
Non-specific Immunogenomic signature associated with ICI-related pneumonitis in non-small-cell lung cancer (NSCLC) patients. #4247 Rapid Oral

Basic Science and Translational Research

Sunday 25.10.2026
09:14 – 09:19 CET
Breast cancer
Giredestrant Patient (pt)-reported outcomes (PROs) from the phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2− eBC). #538 Rapid Oral

Breast Cancer, Early-Stage

Friday 23.10.2026
16:20 – 16:25 CEST
Giredestrant Retrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2− aBC) in the post-CDK4/6 inhibitor (I) setting. #2 Rapid Oral

Breast Cancer, Advanced Stage

Saturday 24.10.2026
10:20 – 10:25 CEST
Giredestrant Updated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS Breast Cancer (BC): A phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2− LA/mBC). #23 Poster

Advanced Breast Cancer, Other

Saturday 24.10.2026
12:00 – 12:45 CEST
Pertuzumab Real-world eligibility for DESTINY-Breast11 (DB-11) neoadjuvant escalation criteria and outcomes of DB-11-eligible vs DB-11-ineligible patients with HER2-positive early breast cancer (HER2+ eBC). #594 Poster

Breast Cancer, Early-Stage

Saturday 24.10.2026
12:00 – 12:45 CEST
ZN-1041 BREnnA: Phase II/III randomised study of ZN-A-1041 or tucatinib (TUC), in combination with trastuzumab + capecitabine (HX), in patients with HER2-positive locally advanced or metastatic breast cancer (HER2+LA/mBC) with or without central nervous system (CNS) metastases. #1796 TiP Poster

HER2+ Breast Cancer

Saturday 24.10.2026
12:00 – 12:45 CEST
Solid tumours
Tam-Peli
Tambotatug pelitecan (YL201): Analyses of interstitial lung disease in patients with advanced solid tumours from phase I/II studies. #1057 Poster

Developmental Therapeutics

Friday 23.10.2026
15:15 – 16:00 CEST
YL211 (cMET ADC) Phase I First-in-Human (FIH) Results of YL211, a c-Met targeting Antibody-Drug Conjugate (ADC), in patients (pts) with advanced solid tumors. #1017 Poster

Developmental Therapeutics

Friday 23.10.2026
15:15 – 16:00 CEST
Tam-Peli
Tam-Peli versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): a multicenter, randomised, open-label, phase III study (TAISHAN-301). #LBA43 Proffered Paper Session

Head and Neck Cancer

Sunday 25.10.2026
08:40 – 08:50 CET
Tecentriq (atezolizumab) + Avastin (bevacizumab) Outcomes by baseline tumor burden using 6-and-12 scores and the up-to-7 criteria in TALENTACE: phase III study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo/Bev) or on demand TACE alone in patients with systemically untreated, unresectable hepatocellular carcinoma (uHCC). #1700 ePoster

Hepatocellular Carcinoma
Tecentriq (atezolizumab) ATOMIC (A021502/AIO-KRK-0317): Presentation and outcomes in patients (pts) with stage III d-MMR early-onset colon cancer (EOCC) and average-onset colon cancer (AOCC). #858 Poster

Colon Cancer

Sunday 25.10.2026
12:00 – 12:45 CET
Tecentriq (atezolizumab) Adjuvant atezolizumab in patients with MSI-high/MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy: the phase II ANTONIO-study (AIO-KRK-0220). #802 Poster

Colon Cancer

Sunday 25.10.2026
12:00 – 12:45 CET

(Press release, Hoffmann-La Roche, OCT 19, 2026, View Source [SID1234673601])